+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasal Polyposis - Pipeline Insight, 2021

  • ID: 5262006
  • Drug Pipelines
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Allakos
  • AstraZeneca.
  • Idorsia Pharmaceuticals
  • Novartis
This “Nasal Polyposis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Nasal Polyposis Understanding

Nasal Polyposis: Overview

A nasal polyp (also called nasal polyposis) is a benign (noncancerous) tumor that grows from the lining of the nose or sinuses. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make your nose feel stuffy, and can decrease your sense of smell. Not all growths in the nose are polyps. Nasal polyps may result from chronic (long-lasting) inflammation of the lining of the nose, although they often occur for no apparent reason. People with chronic hay fever (allergic rhinitis) are more likely than others to develop nasal polyps. In addition, nasal polyps commonly develop in children with cystic fibrosis.

"Nasal Polyposis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyposis pipeline landscape is provided which includes the disease overview and Nasal Polyposis treatment guidelines. The assessment part of the report embraces, in depth Nasal Polyposis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyposis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyposis R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyposis.
Nasal Polyposis Emerging Drugs Chapters

This segment of the Nasal Polyposis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nasal Polyposis Emerging Drugs
  • Benralizumab: AstraZeneca
Benralizumab is a monoclonal antibody that attracts natural killer cells via antibody-dependent cellular cytotoxicity activity (ADCC activity) to induce direct and rapid depletion of eosinophils in the blood and in the airway. The drug is in phase 3 of clinical trials for the treatment of severe nasal polyposis.
  • AK001: Allakos
AK001 is a therapeutic antibody that targets a receptor present on eosinophils and mast cells. Binding of antibody to this receptor causes inhibition of mast cell activity and selective depletion of activated eosinophils. AK001's action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of conditions where these cells are involved. It is currently in phase 2 of clinical trial for the treatment of nasal polyposis.

Nasal Polyposis: Therapeutic Assessment

This segment of the report provides insights about the different Nasal Polyposis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nasal Polyposis

There are approx. 4+ key companies which are developing the therapies for Nasal Polyposis. The companies which have their Nasal Polyposis drug candidates in the most advanced stage, i.e. phase III include AstraZeneca.

The report covers around 4+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Nasal Polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nasal Polyposis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyposis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyposis drugs.

Nasal Polyposis Report Insights
  • Nasal Polyposis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Nasal Polyposis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Nasal Polyposis drugs?
  • How many Nasal Polyposis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasal Polyposis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyposis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nasal Polyposis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • AstraZeneca.
  • Allakos
  • Idorsia Pharmaceuticals
  • Novartis
Key Products
  • Benralizumab
  • AK001
  • ACT-774312
  • Fevipiprant
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allakos
  • AstraZeneca.
  • Idorsia Pharmaceuticals
  • Novartis
Introduction

Executive Summary

Nasal Polyposis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Nasal Polyposis - Analytical Perspective

In-depth Commercial Assessment
  • Nasal Polyposis companies' collaborations, Licensing, Acquisition - Deal Value Trends
Nasal Polyposis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
late Stage Products (Phase III)
  • Comparative Analysis
Benralizumab: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
AK001: Allakos
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Nasal Polyposis Key Companies

Nasal Polyposis Key Products

Nasal Polyposis - Unmet Needs

Nasal Polyposis - Market Drivers and Barriers

Nasal Polyposis - Future Perspectives and Conclusion

Nasal Polyposis Analyst Views

Nasal Polyposis Key Companies

Appendix

List of Tables
Table 1 Total Products for Nasal Polyposis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Nasal Polyposis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • AstraZeneca.
  • Allakos
  • Idorsia Pharmaceuticals
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll